BR9809330A - Halotherapy development process - Google Patents
Halotherapy development processInfo
- Publication number
- BR9809330A BR9809330A BR9809330-4A BR9809330A BR9809330A BR 9809330 A BR9809330 A BR 9809330A BR 9809330 A BR9809330 A BR 9809330A BR 9809330 A BR9809330 A BR 9809330A
- Authority
- BR
- Brazil
- Prior art keywords
- powder
- halotherapy
- dispenser
- dosage
- user
- Prior art date
Links
Abstract
Patente de Invenção: <B>"PROCESSO DE DESENVOLVIMENTO DE HALOTERAPIA"<D>. Processo para prover a haloterapia à parte superior (22-26) do trato respiratório inferior (20), o qual inclui as etapas de operação de um dispensador (30) e de inalação. O dispensador (30) contém um pó de cloreto de sódio seco. O usuário opera o dispensador (30) para liberar uma dosagem de pó para inalação, quando o dispensador (30) for direcionado para a boca do usuário. O usuário inala então a dosagem de pó através da boca. Devido ao fato de o pó apresentar uma faixa de tamanho de partícula que permite que o pó atinja a parte superior (22-26) do trato respiratório inferior (20) sem ser introduzido nos pulmões do usuário, a dosagem do pó seco apresenta uma concentração na parte superior (22-26) suficiente para prover a eficaz haloterapia. O tamanho de partícula preferido é de cerca de 5 mícrons a cerca de 20 mícrons. A dosagem preferida é de cerca de 3 miligramas de pó.Invention Patent: <B> "HALOTHERAPY DEVELOPMENT PROCESS" <D>. Process for providing halotherapy to the upper part (22-26) of the lower respiratory tract (20), which includes the steps of operating a dispenser (30) and inhalation. The dispenser (30) contains a dry sodium chloride powder. The user operates the dispenser (30) to release a dosage of powder for inhalation when the dispenser (30) is directed to the user's mouth. The user then inhales the powder dosage through the mouth. Due to the fact that the powder has a particle size range that allows the powder to reach the upper part (22-26) of the lower respiratory tract (20) without being introduced into the user's lungs, the dry powder dosage presents a concentration at the top (22-26) enough to provide effective halotherapy. The preferred particle size is about 5 microns to about 20 microns. The preferred dosage is about 3 milligrams of powder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81413297A | 1997-04-29 | 1997-04-29 | |
PCT/US1998/008372 WO1998048875A1 (en) | 1997-04-29 | 1998-04-29 | Method of delivering halotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9809330A true BR9809330A (en) | 2000-07-04 |
Family
ID=25214258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9809330-4A BR9809330A (en) | 1997-04-29 | 1998-04-29 | Halotherapy development process |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR9809330A (en) |
-
1998
- 1998-04-29 BR BR9809330-4A patent/BR9809330A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2210717C (en) | An inhaler | |
AU612333B2 (en) | Inhalation device | |
IS1796B (en) | Inhaled polypeptide formulation composition which also contains an enhancer compound | |
BR9814928A (en) | Inhalation device for administering powdered medication | |
NZ507151A (en) | Pulmonary and nasal delivery of raloxifene | |
IS1768B (en) | Inhalant pharmaceutical composition containing insulin | |
NO995251L (en) | Method of administration of halotherapy | |
NO950368D0 (en) | inhaler | |
US20120174917A1 (en) | Press-type medical nebulizer and pressing means thereof | |
EA013180B1 (en) | Improvement of a dry powder inhaler | |
ATE240759T1 (en) | MEDICINAL ADMINISTRATION AND PACKAGING | |
CA2614628A1 (en) | Inhalation device with a bottom surface formed as a foot | |
BR0017519B8 (en) | medicine capsule for an inhaler, and process for manufacturing a capsule comprising a powdered medicine. | |
BR0107304A (en) | Inhalation powder containing tiotropium | |
YU56600A (en) | Device for delivering an active agent to the lung of a human patient | |
ES2179831T3 (en) | RELEASE IN THE LUNGS OF ACTIVE FRAGMENTS OF PARTIROIDIAN HORMONE. | |
TW200607538A (en) | Medicament inhaler device | |
ZA200710957B (en) | Inhalator capsules | |
MX9704544A (en) | Therapeutic preparation for inhalation containing parathyroid hormone, pth. | |
EP1224003B8 (en) | Combination mouthpiece for inhalation therapy devices used by oxygen dependent patients | |
BR9809330A (en) | Halotherapy development process | |
NO993540L (en) | New formulation for inhalation having bulk density at a slope of 0.28 to 0.38 g / ml, comprising tebutaline sulfate, a process for the preparation of the formulation and its use | |
JPH05123398A (en) | Throat protection inhalation agent and inhalation instrument | |
CA2465266C (en) | Inhalation device for dry powder controlled by inspiration | |
KR102280232B1 (en) | mask |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |